Table 3 A) distribution of HPV-RNA positivity over groups with cytology scores NILM and ASCUS+ (reason for referral to a gynecologist). B) distribution of HPV-RNA positivity in scrapes from women with an outcome <CIN2+ and >CIN2+ (median follow up 7 months)
A | B | ||||||
NILM | ASCUS+ | sens: 83% | <CIN2 | CIN2+ | sens: 81% | ||
hrHPVE6/7 neg | 197 | 36 | spec: 65% | hrHPVE6/7 neg | 217 | 37 | spec: 48% |
hrHPVE6/7 pos | 96 | 177 | NPV=85% | hrHPVE6/7 pos | 165 | 155 | NPV=85% |
PPV=66% | PPV=48% | ||||||
sens:52% | sens:56% | ||||||
hrHPVE6* neg | 256 | 103 | spec: 75% | hrHPVE6* neg | 318 | 85 | spec: 59% |
hrHPVE6* pos | 37 | 110 | NPV:71% | hrHPVE6* pos | 75 | 107 | NPV:79% |
PPV: 75% | PPV: 59% | ||||||